AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29096996 — intervention group
Group type: COMPARATOR
Intervention: NTG patients and healthy volunteers
Number of subjects: 13
Study 29097234 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal resection
Number of subjects: 10
Study 29097417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HIV in care with viral loads >1500 copies/mL
Number of subjects: 1315
Study 29097417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active participants
Number of subjects: 1315
Study 29097417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active participants with condomless anal or vaginal sex with an at-risk partner
Number of subjects: 1315
Study 29097417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HIV in care with high viral loads and concurrent risk behaviour
Number of subjects: 1315
Study 29097449 — intervention group
Group type: EXPERIMENTAL
Intervention: CD16-dependent NK cell activation markers
Number of subjects: 103
Study 29097449 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR3A-VV genotype frequency
Number of subjects: 103
Study 29097500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioclinical model based on clinical and molecular predictors
Number of subjects: 91
Study 29097500 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining for CD10, BCL6, MUM1/IRF4, FOXP1, LMO2, BCL2, MYC, P53, and phosphoSTAT3 (pySTAT3) expression
Number of subjects: 91
Study 29098088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute (3%) povidone-iodine solution through a low-pressure pulsatile device
Number of subjects: 50
Study 29098088 — intervention group
Group type: COMPARATOR
Intervention: Saline solution through a bulb syringe
Number of subjects: 50
Study 29098288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulator therapy
Number of subjects: 6
Study 29098299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-releasing implant (370 µg of mometasone furoate) placed in the frontal sinus ostia (FSO) after endoscopic sinus surgery (ESS)
Number of subjects: 80
Study 29098299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid-releasing implant
Number of subjects: 80
Study 29098299 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 80
Study 29098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage intake (SSB)
Number of subjects: 34748
Study 29098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestive interaction with a genetic variant in the ChREBP-FGF21 pathway (discovery cohorts)
Number of subjects: 34748
Study 29098467 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB)
Number of subjects: 92
Study 29098467 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 92
Study 29098467 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 92
Study 29099620 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC% improvement by ≥MCID
Number of subjects: 300
Study 29099620 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC% worsening ≥MCID
Number of subjects: 300
Study 29099620 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC% reliability
Number of subjects: 300
Study 29099620 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID estimates for FVC% improvement
Number of subjects: 300
Study 29099620 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID estimates for FVC% worsening
Number of subjects: 300
Study 29099942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-specific-activity I-131 meta-iodobenzylguanidine (MIBG) therapy at a maximum tolerated dose (MTD) of 296 MBq/kg.
Number of subjects: 21
Study 29099942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-specific-activity I-131 MIBG therapy
Number of subjects: 21
Study 29100190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 12
Study 29100190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg every 3 weeks
Number of subjects: 12
Study 29100192 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care excision of melanoma
Number of subjects: 9367
Study 29100192 — intervention group
Group type: COMPARATOR
Intervention: Secondary care excision of melanoma
Number of subjects: 9367
Study 29100412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (7.5mg daily) added to spironolactone
Number of subjects: 30
Study 29101020 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR)
Number of subjects: 308
Study 29101147 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPPY Hearts screening protocol
Number of subjects: 1000
Study 29101147 — intervention group
Group type: COMPARATOR
Intervention: Framingham Risk Score
Number of subjects: 1000
Study 29101272 — intervention group
Group type: EXPERIMENTAL
Intervention: Dystroglycanopathy (DG) cohort
Number of subjects: 52
Study 29101272 — intervention group
Group type: COMPARATOR
Intervention: Duchenne-Becker muscular dystrophy (DBMD) cohort
Number of subjects: 52
Study 29101287 — intervention group
Group type: EXPERIMENTAL
Intervention: European Society of Cardiology 0/1-hour algorithm using hs-cTnT and hs-cTnI in patients with RD
Number of subjects: 487
Study 29101287 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications of the rule-in and rule-out thresholds
Number of subjects: 487
Study 29101287 — intervention group
Group type: COMPARATOR
Intervention: Patients with RD
Number of subjects: 487
Study 29101287 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal renal function
Number of subjects: 487
Study 29101463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dovitinib (300 mg in 5 days on/2 days off schedule) with fluvoxamine
Number of subjects: 45
Study 29101463 — intervention group
Group type: COMPARATOR
Intervention: Dovitinib (300 mg in 5 days on/2 days off schedule) without fluvoxamine
Number of subjects: 45
Study 29101542 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet based on REE measured by indirect calorimetry
Number of subjects: 355
Study 29101542 — intervention group
Group type: COMPARATOR
Intervention: Diet based on REE estimated by Harris-Benedict equation
Number of subjects: 355
Study 29101797 — intervention group
Group type: EXPERIMENTAL
Intervention: Amber-tinted blue light-blocking lenses
Number of subjects: 14
Study 29101797 — intervention group
Group type: COMPARATOR
Intervention: Clear placebo lenses
Number of subjects: 14
Study 29101862 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial blood glucose levels
Number of subjects: 87
Study 29101862 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 87
Study 29102040 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TPO antibodies
Number of subjects: 1468
Study 29102040 — intervention group
Group type: COMPARATOR
Intervention: TSH ≥2.5 mIU/L
Number of subjects: 1468
Study 29102458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system for nurses to facilitate tobacco smoke exposure screening and counseling
Number of subjects: 0
Study 29102458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system
Number of subjects: 0
Study 29102579 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthesis
Number of subjects: 1030
Study 29102688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair system (MVRS) via small left thoracotomy
Number of subjects: 30
Study 29102689 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR) with a self-expanding, nitinol valve with bovine pericardial leaflets, median deployment time: 14 min (interquartile range: 12 to 17 min).
Number of subjects: 50
Study 29102811 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal iliac artery ligation (IIAL) for postpartum hemorrhage (PPH)
Number of subjects: 0
Study 29102811 — intervention group
Group type: COMPARATOR
Intervention: Healthy postpartum women (control group)
Number of subjects: 0
Study 29102811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IIAL and control)
Number of subjects: 0
Study 29102831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deficit for rate of force development (RFD) 0-50ms
Number of subjects: 14
Study 29102831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deficit for rate of force development (RFD) 0-50ms after controlling for physical activity level
Number of subjects: 14
Study 29103084 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced staplers during distal pancreatectomy
Number of subjects: 121
Study 29103666 — intervention group
Group type: EXPERIMENTAL
Intervention: PI3KR1-rs706716
Number of subjects: 342
Study 29103666 — intervention group
Group type: EXPERIMENTAL
Intervention: AKT1-rs3803304, AKT2-rs3730050, PDK1-rs11686903, PI3KR1-rs706716
Number of subjects: 342
Study 29103916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + Torcetrapib
Number of subjects: 0
Study 29103916 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin + Placebo
Number of subjects: 0
Study 29104758 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised MSIS-29 scoring structure
Number of subjects: 0
Study 29104758 — intervention group
Group type: COMPARATOR
Intervention: Original MSIS-29 scoring structure
Number of subjects: 0
Study 29105003 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 960
Study 29105003 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 960
Study 29105003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 960
Study 29105003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety or severe AIA at baseline
Number of subjects: 960
Study 29105003 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, irritability, and severe AIA
Number of subjects: 960
Study 29105491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of enacted stigma
Number of subjects: 188
Study 29105491 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-devaluation
Number of subjects: 188
Study 29105491 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight self-stigma variables
Number of subjects: 188
Study 29106816 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0
Study 29106816 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 0
Study 29107010 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 1142
Study 29107010 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 1142
Study 29107010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-biomarker strategy combining hs-cTnI and BNP with CJb
Number of subjects: 1142
Study 29107051 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetaben PET scans
Number of subjects: 205
Study 29107441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea, median treatment duration 7 years, mean therapeutic dose 18±4.7 mg/kg/day
Number of subjects: 652
Study 29107441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 652
Study 29107621 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (30 mg/kg)
Number of subjects: 311
Study 29108000 — intervention group
Group type: EXPERIMENTAL
Intervention: Missense variants in CD101
Number of subjects: 100
Study 29108000 — intervention group
Group type: EXPERIMENTAL
Intervention: Missense/5' UTR variant in UBE2V1 (among women)
Number of subjects: 100
Study 29109077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of mRNA-transfected c-Met-CAR T cells (3 × 10^6 cells)
Number of subjects: 0
Study 29109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study 29110152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab (plus endocrine therapy for ER-positive tumors)
Number of subjects: 64
Study 29110709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/piperaquine (DP)
Number of subjects: 150
Study 29110709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29110846 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation testing in aNSCLC patients
Number of subjects: 3382
Study 29110846 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation testing in Caucasian squamous NSCLC patients
Number of subjects: 3382
Study 29110846 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation status concordance between tissue/cytology and plasma samples
Number of subjects: 3382
Study 29110849 — intervention group
Group type: COMPARATOR
Intervention: Afatinib monotherapy (40mg daily)
Number of subjects: 73
Study 29110849 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab (afatinib 40mg daily + cetuximab 500mg/m)
Number of subjects: 73
Study 29110849 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients who received afatinib monotherapy for ≥12 weeks
Number of subjects: 73
Study 29110849 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients who received afatinib monotherapy for <12 weeks
Number of subjects: 73
Study 29110849 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients with T790M-positive tumors
Number of subjects: 73
Study 29110849 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab for patients with T790M-negative tumors
Number of subjects: 73
Study 29110849 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus cetuximab
Number of subjects: 73
Study 29110849 — intervention group
Group type: COMPARATOR
Intervention: Afatinib monotherapy
Number of subjects: 73
Study 29110945 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29111011 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab therapy
Number of subjects: 48
Study 29112084 — intervention group
Group type: EXPERIMENTAL
Intervention: Feed-related splanchnic oxygenation (SrSO2) monitoring during enteral feeding introduction and full enteral feeding (FEF) achievement.
Number of subjects: 20
Study 29112329 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04171327 (fosdagrocorat)
Number of subjects: 12
Study 29112329 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 12
Study 29112593 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical LPDFs in MRA women
Number of subjects: 25
Study 29112593 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical LPDFs in ARA women
Number of subjects: 25
Study 29112593 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical LPDFs in ARA women
Number of subjects: 25
Study 29112634 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with sympathomimetic drugs and fluid therapy
Number of subjects: 21
Study 29112634 — intervention group
Group type: COMPARATOR
Intervention: Non-responders (NR)
Number of subjects: 21
Study 29112634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BP target of 65 mmHg
Number of subjects: 21
Study 29112634 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity (BRS)
Number of subjects: 21
Study 29112634 — intervention group
Group type: EXPERIMENTAL
Intervention: BP variability, HR variability, and baroreflex trends
Number of subjects: 21
Study 29112650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500-mL intravenous fluid bolus
Number of subjects: 276
Study 29112650 — intervention group
Group type: COMPARATOR
Intervention: 500-mL intravenous fluid bolus
Number of subjects: 276
Study 29112650 — intervention group
Group type: COMPARATOR
Intervention: Reference group (admission pulse pressure 50 mm Hg or greater)
Number of subjects: 276
Study 29112672 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical curettage (ECC)
Number of subjects: 204
Study 29112763 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (40/30 mg, 20/15 mg)
Number of subjects: 1518
Study 29112763 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 1518
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of low-fibre grain products
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of vegetable protein
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of sugar-sweetened beverages
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity
Number of subjects: 431
Study 29112780 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sedentary behaviour
Number of subjects: 431
Study 29113961 — intervention group
Group type: EXPERIMENTAL
Intervention: mMammogram intervention group (n=60)
Number of subjects: 120
Study 29113961 — intervention group
Group type: COMPARATOR
Intervention: usual care control group (n=60)
Number of subjects: 120
Study 29113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular complications
Number of subjects: 0
Study 29113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 0
Study 29113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular disease of the lower limbs
Number of subjects: 0
Study 29113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular disease of the cerebral vessels
Number of subjects: 0
Study 29113984 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 0
Study 29114094 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2176
Study 29114094 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk algorithm
Number of subjects: 2176
Study 29115994 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VLX) + O-demethyl-venlafaxine (ODV) concentrations measured after phenotyping visit.
Number of subjects: 205
Study 29115994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine administered to assess drug metabolizing enzymes activity.
Number of subjects: 205
Study 29115994 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visits for efficacy, tolerance, and observance assessment.
Number of subjects: 205
Study 29116022 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement project targeting diabetes prevention
Number of subjects: 0
Study 29116022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-site research implementation studies focusing on cardiovascular risk prevention
Number of subjects: 0
Study 29116022 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care to address women Veterans' mental health treatment needs
Number of subjects: 0
Study 29116031 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC-NTF cells
Number of subjects: 0
Study 29116050 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 3408
Study 29116050 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LAM)
Number of subjects: 3408
Study 29116972 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic global longitudinal strain (GLS) obtained during intraoperative transesophageal echocardiogram before cardiopulmonary bypass.
Number of subjects: 275
Study 29116972 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS value
Number of subjects: 275
Study 29116972 — intervention group
Group type: COMPARATOR
Intervention: First predictive model without GLS
Number of subjects: 275
Study 29116972 — intervention group
Group type: EXPERIMENTAL
Intervention: Second predictive model with GLS
Number of subjects: 275
Study 29117930 — intervention group
Group type: EXPERIMENTAL
Intervention: NMIBC-SI (Patient-Reported Symptom Index)
Number of subjects: 450
Study 29118225 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 0
Study 29118984 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermoDox® with ultrasound-mediated hyperthermia
Number of subjects: 0
Study 29118984 — intervention group
Group type: COMPARATOR
Intervention: ThermoDox® (Part 1)
Number of subjects: 0
Study 29118984 — intervention group
Group type: COMPARATOR
Intervention: ThermoDox® (Part 2)
Number of subjects: 0
Study 29118984 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study 29118984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary outcomes
Number of subjects: 0
Study 29119276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine, nab-paclitaxel, and pembrolizumab (GNP)
Number of subjects: 17
Study 29119917 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli PNP delivered via recombinant adenoviral vector followed by systemic administration of fludarabine phosphate
Number of subjects: 0
Study 29119917 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli PNP
Number of subjects: 0
Study 29121278 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal alpha-delta EEG pattern (delta power >20 dB, alpha power >10 dB)
Number of subjects: 90
Study 29121278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and less volatile anaesthetic co-administration
Number of subjects: 90
Study 29121278 — intervention group
Group type: COMPARATOR
Intervention: Depth-of-anaesthesia indices
Number of subjects: 90
Study 29121645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib treatment for a median of nine months
Number of subjects: 31
Study 29121645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib treatment
Number of subjects: 31
Study 29121934 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day for 12 weeks
Number of subjects: 20
Study 29121934 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 20
Study 29122619 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (single-agent)
Number of subjects: 207
Study 29122619 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib plus paclitaxel
Number of subjects: 207